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ABSTRACT

Wieczerzak, Krystyna Blanka. Department of Neuroscience, Cell Biology, & Physiology,
Wright State University, 2015. Sensorimotor Analysis of Oxaliplatin treated rats

There is currently no direct evidence that chemotherapy induced peripheral
neuropathy (CIPN) necessarily explains the sensorimotor deficits seen in 90% patients
treated with oxaliplatin (OX). Some patients develop sensory symptoms without CIPN.
Our laboratory reported abnormal signaling from IA afferents in OX treated rats with no
evidence of neuropathy. We hypothesized that in the absence of CIPN, the behavioral
disability is associated with impaired sensory encoding in OX treated rats. The purpose of
this study was to investigate the sensorimotor abilities of OX treated rats. The battery of
behavioral tests was designed to address proprioception and sensorimotor integration. In
the absence of CIPN, few OX rats revealed signs of decreased performance, as compared
to controls. In conclusion, this study reproduced some of the results seen in the clinical
studies and established a rat model, which can be used in further investigation of chronic
sensorimotor symptoms of OX.
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I.

INTRODUCTION

Antineoplastic agent oxaliplatin (OX) is one of the most effective treatments
against advanced and metastatic digestive tumors such as colorectal cancer with the result
that patients are among the third largest group of cancer survivors (Ganz, 2003).
Furthermore, OX also exhibits promising antitumor activity effective in the treatment of
number of other malignancies such as: rectal, pancreatic (Louvet, et al., 2002), gastric,
ovarian (Dieras, et al., 2002; Piccart, et al., 2001), non-small-cell lung (Monnet, et al.,
1998), breast cancer (Garutic, et al., 2001), and non-Hodgkin lymphoma (Chau, et al.,
2001).
Oxaliplatin a third-generation organoplatinum compound was discovered in 1976
at Nagoya City University by Prof. Yoshinori Kidani (Di Francesco, et al., 2002) and was
first introduced into clinical trials in 1986 by Mathe (Mathe, et al., 1986). Like other
platinum compounds, OX is a DNA alkylating agent believed to form inter-, and intrastrand cross-links in DNA that prevent DNA synthesis, replication and transcription
leading to cell apoptosis (Ta, et al., 2006; Barbec and Kasparkova, 2005). Contrary to its
precursor cisplatin (Extra,et al., 1990), OX treatment is not associated with dose limiting
symptoms such as nephrotoxicity (Fillastre and Rguenez-Viotte, 1989), ototoxicity, or
myelotoxicity (Nguyen, et al., 1981). Moreover, the efficiency of cisplatin is often
limited by acquired and/or intrinsic resistance, which does not occur in OX-treatment
(Extra, et al., 1990).
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Although OX is a leading chemotherapy for various malignancies, acute and/or
chronic neurotoxic side effects are common. These acute and transient neurotoxic
symptoms are observed in 85-95% of patients (Park,et al., 2009a), and are manifested
during or shortly after the infusion as dysesthesias, muscle spasm, hyperalgesia, and
hypersensitivity to cold (Dropcho, 2011). These symptoms are not dose dependent, and
are typically resolved between treatments (Lehky, et al., 2004). Chronic symptoms
include distal dysesthesias, sensory ataxia, proprioceptive deficits and functional
impairment (Dropcho, 2011; Krishnan, et al., 2005). Unlike the acute symptoms, chronic
neurotoxicity develops with an increase in cumulative dose, and leads to a dose reduction
or even cessation of the treatment preventing up to 80% of patients from receiving a full
dose, decreasing their chances of survival (Bennet, et al., 2012). Despite the claims of
reversibility within 1 year (Andre, et al., 2004), studies have shown that in 79% of
patients the chronic symptoms can persist even 2 years since the last dose, leading to
decreased quality of life in those patients (Park, et al., 2011). Furthermore, there were
reported cases of patients who experienced worsening of symptoms (a phenomenon
called “coasting”) after treatment was discontinued (Bennet, et al., 2012; Burakgazi, et al.
2011).
Standardized patient evaluations such as National Cancer Institute Common
Toxicity Criteria (NCI-CTC) are commonly used to diagnose these chronic symptoms as
chemotherapy induced peripheral neuropathy (CIPN) (National Cancer Institute:Common
Toxicity Criteria version 2.0 1999). However, the clinical assessment of CIPN is very
ambiguous and varies in terms of the grading scale used, and the interpretation of those
scales (Postma, et al., 1998). Direct evaluation of the symptoms done by
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electrophysiological examinations of patients treated with OX provide further and more
direct evidence of neuropathy such as reductions in amplitude of electrically-evoked
sensory nerve action potentials and in density of intra-epidermal nerve fibers (Koskinen,
et al., 2011; Park, et al., 2009b).
A clinical at John’s Hopkins reported several patients developing prominent
symptoms such as difficulty drinking, walking, and performing dexterity tasks with no
evidence of axonal loss indicating that CIPN might not be entirely responsible for OX
chronic side effects (Burakgazi, et al., 2011). The clinical assessment of CIPN is strongly
biased towards patients symptoms obtained from standardized evaluations, suggesting the
possibility that in some patients, the chronic OX-induced symptoms of sensorimotor
deficit may be in fact misdiagnosed as CIPN (Burakgazi, et al., 2011; Frigeni, et al.,
2011). Furthermore, our laboratory reported evidence that chronic OX- treatment leads to
corrupted peripheral signal transduction/encoding by muscle receptors in the absence of
CIPN (Bullinger, et al., 2011). In an intact animal, the intra-axonal recordings from large
diameter proprioceptive afferents that supply muscle spindle receptors (group IA and II
afferents) and tendon organ receptors (group IB afferents) fire continuously throughout
the static muscle stretch, hence they are known to be slowly adapting (Matthews, 1972).
However, following a chronic OX treatment, up to 50% of proprioceptive afferents
became “fast adapting” and ceased to fire in under 0.5 sec (Bullinger, et al., 2011).
The signal produced by the proprioceptive afferents provides the central nervous
system (CNS) with a sensory feedback that is crucial in proper movement control,
general sense of body position in space (proprioception) and body movement
(kinesthesia). Hence, these afferents play an essential role in stabilizing body position and
3

ensuring precise trajectory of limbs (Proske, 2005; Proske and Gandevia, 2009a; Proske
and Gandevia 2012). The patients that suffer from OX-induced chronic symptoms often
described their deficits as “problems with balance”, “feeling unsure and unsteady”,
“having difficulty walking”, “problems when driving”, “getting very clumsy”, “nearly
falling over” (Bennet, et al., 2012). Although those symptoms could be elicited by dyingback neuropathy such as CIPN, other deficits in proprioceptive signal transduction have
to be manifested through similar symptoms. Therefore, we hypothesized that the
behavioral disability, in the absence of CIPN, is associated with impaired sensory
encoding in OX treated rats.
The main purpose of this study was to reproduce the results seen in several
patients from the Burakgazi study (2011), i.e. the presence of chronic sensorimotor
deficits, without the evidence of CIPN, in a rat model following the OX-treatment. The
secondary goal was to determine if the changes in physiological encoding of muscle
proprioceptors are associated with the sensorimotor deficits upon OX treatment. Complex
motor coordination and proprioceptive abilities of OX treated animals were measured by
behavioral tasks known to be sensitive to sensorimotor deficits: paw placement (De
Ryck, et al., 1989; Madinier, et al., 2014) and ladder rung skilled walking task (Metz and
Whishaw, 2002) in the horizontal, upward and downward plane (Antonow-Schlorke, et
al., 2013). Additionally, specifically for the purpose of this study we have designed a
novel modification to the common balance beam test (Hicks and D'Amato, 1974;
Helgren, et al., 1997) by adding four 90˚ turns. Although it did not show a prominent
difference between the OX and control animals, it showed a tendency towards easier and
more secure approaches to the corner, as compared with the control animals.
4

Unlike the acute symptoms, the chronic sensorimotor deficits are not widely
addressed in rat models and, furthermore there is no published study presenting chronic
proprioceptive deficits in rats following the OX treatment. In the current situation, there
is no apparent evidence that the dose-limiting (Bennet, et al. 2012), chronic sensorimotor
deficits are caused by the CIPN. Thus, developing the rat model is crucial in order to
study this problem that prevents up to 80% cancer patients from receiving a full dose
decreasing their chance of survival (Park, et al. 2009b).
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II. METHODS
Animals
All the procedures were carried with an approval of the Wright State University
Laboratory Animal Care and Use Committee. The data were collected from 15 adult
female Wistar rats weighting 240-250g at the beginning of the experiment. The animals
were housed individually in barrier-protected cages in a 12 hours light-dark cycle with
water and food ad libitum. 10 rats, randomly selected, were subjected to the oxaliplatin
treatment (OX) and the rest were given vehicle control injections (VC). The animals were
monitored daily for signs of distress and body weight loss. All animals were euthanized
by overdose with 5% isofluorane after terminal experiment.
Experimental Design
The training for the ladder rung and modified balance beam test was done one
week before the control data collection. The paw placement test does not require training
(De Ryck, et al., 1989) thus it was not performed during the training week. The rats were
trained to cross the horizontal ladder rung in two trials (Antonow-Schlorke, et al., 2013),
and to cross the modified balance beam in three trials (Helgren, et al., 1997). In the
following weeks all animals were subjected to OX or VC treatment (except control week
0 and week 4 due to problems with OX supply), Sensory Nerve Action Potentials
(SNAPs) recording and the blood sample collection was performed on the first day of
each week between 8AM-12PM. In order to eliminate the influence of time between the
treatment and the test, each behavioral test was performed on different days each week
6

Table 1
Table 1. Experimental design, presenting the schedule of behavioral tests relatively to the
treatment day. The abbreviations are as follow: OX (30)/VC- injection of the oxaliplatin
to treated animals that gave the cumulative dose of 30mg/kg, or injection of vehicle
control; Blood- blood sample collection from the lateral tail vein; SNAPs- recording of
the Sensory Nerve Action Potentials; MB- Modified Balance Beam test, LR A- Ladder
Rung test with group A (8animlas); LR B- Ladder Rung test with group B (7animals);
PP-Paw Placement test.
Week

Tuesday

Wednesday

Thursday

Training Handling

MB

LR B

LR A

0
Control

Blood, SNAPs

LR A

MB

PP

LR B

1

Blood, SNAPs, OX (10)/VC

PP

LR B

LR A

MB

2

Blood, SNAPs, OX (20)/VC

MB

LR A

LR B

PP

3

Blood, SNAPs, OX (30)/VC

LR B

PP

MB

LR A

4

Blood, SNAPs, no OX

PP+MB

LR A+ B

5

Blood, SNAPs, OX (40)/VC

LR A

PP +MB

LR B

6

Blood, SNAPs, OX (50)/VC

LR B

PP

LR A

MB

7

Blood, SNAPs, OX (60)/VC

LR A

MB

LR B

PP

8

Blood, SNAPs, OX (70)/VC

PP

LR A

MB

LR B

9

Blood, SNAPs

MB

LR B

PP

LR A

10

Blood, SNAPs

LR B

LR A

MB

PP

11

Blood, SNAPs

MB

PP

LR B

LR A

12

Monday

Terminal in-vivo electrophysiology
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Friday

(see Table 1) always between 9AM-12PM. Due to a large amount of trials in the ladder
rung test, the animals were divided into two groups A and B with 8 and 7 rats
respectively.
Treatment
The animals were anesthetized by isoflurane inhalation (2-4% in 95% O2). The
oxaliplatin dissolved in 5% dextrose was administered via IP injection (Bullinger, et al.,
2011) once per week with a single dose of10mg/kg up to a cumulative dose of 70mg/kg.
On the same day the control group was given a dextrose IP injection. Due to the problems
with supplier the OX dose was skipped on the week 4. The blood samples (200-500µL)
were collected from the lateral tail vein for the measurement of complete blood counts.
Following blood collection, all rats received 5ml of Na/Cl via subcutaneous injections in
order to prevent dehydration.
Sensory Nerve Action Potentials recordings
Electrophysiological symptoms of OX-induced dying-back neuropathy in patients
are: axon degeneration and demyelination which are described as decreased amplitude
and increased latency in compound Action Potentials (cAP), respectively (Park, et al.
2009b). Similarly, several studies using rat models also showed reduction in amplitudes
in cAP in the tails of OX-treated rats (Jamieson, et al. 2005). In order to address the
possibility of OX-induced CIPN in the experimental rats, the electrically evoked sensory
nerve action potentials were recorded from control and experimental rat’s tail weekly
throughout the entire study (Novak, et al., 2009).
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Figure 1

9

Fig. 1. Sensory nerve action potential recording set up.
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The animals were fully anesthetized by inhalation of isofluorane (2-3% in 100%
O2). The recording needle electrodes were placed 1cm apart starting a 1cm away from the
base of the tail. The ground electrode was placed 2cm away from the recording electrode.
The stimulating electrodes were placed 2cm away from the ground electrode and 1cm
apart from each other (see the Fig. 1). The electrical stimulus of 10mA was applied to
elicit a SNAP (Novak, et al., 2009)
Signal Encoding in Proprioceptive Afferents
The terminal experiments were performed on all rats 4-5 weeks after the final
treatment with OX or VC alone. Anesthesia was induced and maintained by the
inhalation of isoflurane inhalation (1-3% in 100% O2). The animal’s vitals were
monitored every 15-30min and body temperature was maintained at 37˚C throughout the
entire experiment. After data collection, the rats were euthanized by isoflurane overdose.
Surgical preparation was performed as described previously (Bullinger, et al.,
2011; Haftel, et al., 2004; Haftel, et al., 2005). The triceps surae muscles and their nerves
were dissected and freed of surrounding tissue in the left hind limb, while the rest of
nerves were crushed. The animal was secured in a rigid recording frame and its femur
and tibia were fixed rigidly to the frame with knee and ankle joints at angles of 90˚. The
muscles were attached through their common Achilles tendon to a servomotor, which
measured the force and controlled muscle length. The triceps surae nerves were placed in
continuity on bipolar stimulating electrodes. The dorsal roots at L4 and L5 were exposed
by laminectomy and placed on the bipolar hook electrodes. Individual sensory-axons
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were penetrated with sharp glass micropipettes (25-30Ω, 2M K-acetate) to record action
potentials elicited by various stimuli.
Sensory axons that responded with orthodromic action potentials, and had the
conduction delay of <3ms in response to electrical stimulus in triceps surae, were selected
for further study. Muscle-spindle and tendon-organ afferents were identified by paused
and accelerated firing during the rising phase of force in isometric twitch contractions of
the triceps surae muscle, respectively (Bullinger, et al., 2011). Further, muscle- spindle
afferents were classified as group IA if upon a ramp stretch (20mm/s, 3mm) or triangular
stretch (4mm/s, 3mm) they responded with a high frequency initial burst and if they fired
in response to each cycle of vibrations at the frequencies of ≥100Hz (Matthews, 1972). If
a muscle-spindle afferents did not exhibit high frequency initial burst nor responded to
vibration at the frequencies of ≥100Hz, it was classified as a group II.
The analysis of proprioceptive encoding was made by investigating the firing
response of IA proprioceptive afferents to triceps surae muscles stretch in a ramp-holdrelease paradigm (20mm/s ramp, 3mm). The stretches were repeated every 4 seconds.
The time of occurrence of the last AP during the hold phase of stretch recorded. Records
of afferent action potentials, muscle length, and muscle force were collected, digitized
(20 kHz), and stored on computer for later analysis using Spike2 software (Bullinger, et
al., 2011; Haftel, et al., 2004; Haftel, et al., 2005).
Behavioral Assessment of Proprioceptive Abilities
Ladder Rung and Modified Balance Beam analysis was made by an investigator
blind to the treatment inspecting the video recordings frame-by-frame. The results were
12

analyzed and presented for the following weeks: 0 (control week), 2, 4, 8 (the last week
of treatment) and 10 (two weeks after the treatment). The Paw Placement data was
obtained by life-scoring, done by the blind investigator. The data for tis test was
presented for each week of the study.
Ladder Rung in Horizontal, Downward and Upward dimension
The Ladder Rung test originally designed by Metz and Wishaw (Metz and
Whishaw, 2002; Metz and Whishaw, 2009) has been widely used to assess skilled
walking, limb placement and limb coordination in variety of models of motor
dysfunctions: stroke model (Antonow-Schlorke, 2013; Riek-Burchardt, et al., 2004),
spinal cord injuries (Ghosh, et al., 2009; Martinez, et al. 2010), as well in Parkinson’s
Disease (Metz and Whishaw, 2002; Faraji and Metz, 2007). Low scores and high
error/steps ratios in those studies were concluded as a result of: “skilled motor
impairment”, “proprioceptive impairment” and “impairment in sensorimotor skills”.
Furthermore, as described previously in Antonow-Schlorke et al. (2013), setting
up the ladder rung in an 18˚ angle downward and upward inclinations provided a more
sensitive analysis of motor disabilities. In their study they found that inclining the ladder
rung upward required higher level of motor performance compared to horizontal walking.
The upward inclination also added more load on hind limbs to move the body up, which
provided an additional risk that a limb might slip from a rung if placed incorrectly. The
downward inclination provided an additional challenge in spatial cognition, limb
coordination, weight bearing, and balance (Antonow-Schlorke, 2013).
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Table 2
Table 2. Rating scale for foot placement in the skilled ladder rung walking test
Score
Type
Characteristics
0

Total miss

The limb missed the rung and resulted in paw being
below the rung plane

1

Deep slip

Deep fall after limb slipped off the rung, interrupting
the gait

2

Slight slip

Limb slipped off the rung without causing a fall or
interrupting the gait

3

Replacement

Limb was replaced from one rung to another before
weight bearing

4

Correction

Limb aimed for one rung but was placed on another
Or: Limb position on the same rung was corrected

5

Partial Placement

Limb placed on rung with either toes or heel

6

Correct Placement

Midportion of the limb placed on rung
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The ladder rung apparatus was self-made according to the instructions of Metz
and Wishaw (Metz and Whishaw, 2009). The test was performed in horizontal, upward
and downward position with 5 trials at each (Antonow-Schlorke, 2013). The position of
rungs was randomly assigned for each trial. The distance between rungs was at least 1cm
and no more than 5cm (Metz and Whishaw, 2002).
Foot Fault Analysis: The qualitative evaluation of hind limb placement was
performed using a 7-category scale scoring system introduced previously by Metz and
Whishaw (Metz and Whishaw, 2009) and presented in the table 3. One modification was
made as to the score 0. The original scale defined score 0 as deep fall after limb missed
the rung. In this study, anytime the limb missed the rung and extended the limb below the
level of the rungs was scored as 0 even if this miss did not result in a deep fall. All steps
by hind limbs were analyzed, therefore the last step before and the first step after the stop
were included in the score (Antonow-Schlorke, 2013). The data were averaged and
presented as % of change, i.e. the baseline score obtained during the week 0 served as the
original 100%. Therefore, the positive values indicated the improvement, while the
negative values worsening.
Foot Placement Accuracy Analysis (Number of Errors): As described previously
by Metz and Whishaw (Metz and Whishaw, 2002), the foot placement accuracy was
defined as the number of errors per steps. Based on the scoring system described above,
the error was defined as score 0, 1 and 2. The total number of errors in hind limbs was
calculated with no distinction between right and left, and the mean error/step ratio was
calculated for all five trails and represented as % of error.
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Walking Coordination Analysis: The close investigation of the stepping cycle in
the ladder rung in the control animals in the preliminary experiments revealed a
following walking pattern: left front limb, right hind limb, right front limb and left hind
limb. The hind limb is usually placed at exactly the same rung as the corresponding front
limb. In order to investigate the inter-limb coordination, the stepping sequence along the
whole distance of the ladder rung was inspected. Each time the limb was not used in the
actual cycle in was considered “idle” (Antonow-Schlorke, 2013). The number of times
each limb was idle was counted and then averaged for 5 trials. The result was presented
as the average % of cycles in which the hind limbs were idle.
Hind Foot Placement Precision: In the preliminary study in control animals, it
was observed that the animals tend to place their hind paw in exactly the same rung as the
corresponding front paw. It was hypothesized that in a case of impaired proprioception;
the animal would not be able to place their hind foot precisely at the same rung, since it
could not correctly orient its body in space. The error was defined as any step made by a
hind limb that originally was not placed on the same rung as the proceeding front limb.
Therefore if the foot was placed on the incorrect rung, and then replaced to the correct
one, such a step was still considered an error. A total number of errors was counted and
expressed as an average of error/step ratio for both hind limbs.
Modified Balance Beam
The modification was made based on the previous observations, were OX-treated
rats did not show difficulties in crossing a straight beam, however they seemed to have
problems in placing the foot when they had to step from the straight beam onto a
16

perpendicular pathway. Therefore, the Balance Beam was modified by adding 4 90˚
turns after each 40cm long and 2cm wide straight path. The scoring system was created to
distinguish the mistakes made by slip of the foot and a miss or a swipe which would
indicate that the rat has difficulties orienting their foot in space.
Foot Placement Scoring. The analysis was done using a scoring system as
presented in the Table 2. The analysis was made only for the hind limbs by an
investigator blind to the treatment by studying frame-by-frame the recorded trials. The
average of 4 trials was calculated and recorded for each rat individually. The results were
presented in the form of % improvement; therefore all the values for week 0 are
equalized to 0. The values in the following weeks are the % change of the original value.
The positive values indicate improvement while the negative deterioration of
performance.
Foot Placement Accuracy: The Foot Placement Accuracy measure was inspired
by that used by Metz in the ladder rung test (Metz and Whishaw 2002). The absolute
number of errors (defined as scores 0, 1, 2 and 3) was counted and divided by the total
number of steps.
Corner Analysis: Based on the preliminary data, three different approaches to
corners were defined: Precise- animal moved close to the edge and reposition its body to
be in the same plane as the next path before proceeding. It was indicated by stepping with
an inner feet 1cm away or closer from the edge; Cut- animal step over the corner without
getting close to the edge; Hop- animal jump over the corner so the both hind limbs were
not touching the beam. Additionally, the ratio of errors occurring during a step, or a hop
needed to cross the turn was calculated and expressed as the error/turn ratio.
17

Figure 2
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Fig.2. Modified Balance Beam Apparatus from a top-view. It consists of five 40cm long
and 2cm wide straight paths, interrupted by four 90˚angle turns. The area of 1cm from the
corner was marked, in order to distinguish the precise approach to turning
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Table 3
Table 3. Rating scale for foot placement in the modified balance beam test
Score
Type
Characteristics
0

Fall

Rat fell off the beam after the limb missed or slipped
of the beam

1

Major Slip

Rat lost balance after the limb slipped of the beam

2

Miss/Swipe

Limb missed the beam. Each time is counted

3

Minor Slip

Limb slipped off the beam, without causing the
disturbance to the gait

4

Correction

Limb is placed on the beam and replaced before it is
weight bearing

5

Partial Placement

Majority of the foot is placed on the side of the beam

6

Correct Placement

Majority of the foot is placed on the beam

20

Paw Placement
Paw Placement is one of the most commonly used tests for proprioception in rodent
models. It is used in variety of motor dysfunction, and sensorimotor deficit models such
as: stroke models, cortical ablation, Parkinson’s disease and spinal cord injuries (De
Ryck, et al., 1992). The low scores in this test are concluded to be due to impair
proprioception.
Animals were hold by the body trunk and placed on the table top with all 4 paws.
Next, the rat was moved over to the edge so that the tested limb lost contact with the
surface (De Ryck, et al., 1989). The trial was reported as correct if the rat reacted
immediately and placed its foot on the surface. Missed placement or delayed response
was considered as incorrect. Each animal was subjected to 5 trials testing both hind
limbs. The number of errors for all 5 trials were summed and presented as % of errors.
Differentiating between symptomatic and asymptomatic OX-treated rats
The OX patients develop the symptoms at different cumulative dose and with
different intensity. Furthermore, some do not develop any deficits in sensorimotor
function (Park, et al. 2009a). In order to distinguish the symptomatic rats from
asymptomatic, in all of the behavioral tests the data from control animals was averaged
and represented as mean± 0.95 Confidence Interval, while the data from the OX rats was
presented as a scatterplot with individual points for each animal. This confidence interval
of a mean control value served as a standard range. The animal was considered
symptomatic if it showed a consistent deterioration compering to its own value from the
control week, consistently performed worse than the standard range, and persisted to
perform below the standard range till the week 10. The animals were considered
21

“somehow symptomatic” if they performed worse than the standard range in some weeks,
however scored within the range on week 8 and/or 10.
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III.

RESULTS

Assessment of General Toxicity
Rats showed no sign of distress following the treatment and they maintained
healthy appearance and appetite throughout the entire study. The body weight gain in OX
animals was smaller comparing to VC animals, which is consistent with the systematic
effects of OX in rats (Bullinger, et al., 2011; Cavaletti, et al., 2001) and in humans. The
increase in weight in OX animals was more rapid between week 3 and 5, which correlates
with the date of the missed dose (week 4), further suggesting OX toxic effect (Fig. 3a).
Sensory Nerve Action Potentials recordings
The longitudinal SNAPs recordings showed no evidence of CIPN. Similar to
previous observations from our lab (Bullinger, et al., 2011) and from clinical studies
(Burakgazi, et al., 2011), there were no signs indicating neither axon degeneration nor
demyelination, i.e. there was no significant reduction in SNAPs amplitude or increase in
latency at any point during or after the treatment (Fig.3b and c respectively).
Furthermore, in both OX and VC animals, there was tendency overtime towards larger
amplitudes and shorter latencies, which is a result of maturation of peripheral nerves.
Oxaliplatin Influence on the Sensory Encoding
The IA afferents in OX rats exhibited an apparent failure to sustain the firing
during a static muscle stretch during the hold phase of the ramp-hold-release paradigm
(20mm/s, 3mm). The example of a control slowly adapting and OX rapidly adapting IA
afferent is shown in the figure 4A and B respectively. On average, in the control IA
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Figure 3

A

B

C
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Fig.3. Chronic oxaliplatin toxicity without sensory neuropathy. (A) Plot of control (VC)
and oxaliplatin treated (OX) rats’ average body weight gained; (B) the amplitudes of
Sensory Nerve Action Potentials; (C) the latencies of the SNAPs, all plotted versus time
expressed in weeks, starting with the control week 0

25

Figure 4
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Fig.4. Chronic treatment with oxaliplatin modified the sensory coding in group IA
muscle-spindle afferents. A and B represent the intra-axonal records of action potentials
(APs) recorded from IA afferents in response to ramp-hold-release muscle stretch from
control (A) and OX-treated (B) animals. C represents the time of occurrence of the last
AP during the static hold phase (1s) of the ramp-hold-release paradigm in all IA afferents
sampled per rat. The numbers on the x-axis indicates individual control (1-5) and OXtreated (6-11) rats.
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afferents the last action potential during the hold phase occurred at 935.19±201.79ms. In
the OX IA afferents the last action potential occurred on average at 504.3±404.21ms.
84.1% (37/44) of control and 26.1% (12/46) of OX IA afferents sustained firing through
the most of the hold phase of muscle stretch (≥900ms).
Behavioral Assessment of Proprioceptive Abilities
Ladder Rung in Horizontal, Downward and Upward plane
Foot Fault Score Analysis. The control data for this analysis is presented as a
mean score with 0.95 confidence interval (CI), while the results from OX-treated animals
are shown as a scatterplot, with each individual point corresponding to one rat. The OX
animals that showed consistently a worse performance than standard range are identified
on the plot by an ID-number (see Fig. 5A)
Horizontal. There were three OX animals that felt out of the established standard
range at each of the analyzed weeks: OX 3, OX 9 and OX 10. The OX7 had the %
change in score below the standard on week 2, 4 and 8. OX 3 and OX 9 never reached the
score obtained in the week 0.
Upward. The rats OX3, OX7 and OX 9 were considered symptomatic. OX3 and
OX9 exhibited % score change below the standard range on the week 4, 8 and 10. On
week 2 they both also exhibited decrease in the Foot Fault score as compare to the week
0. OX7 performed worse than on week 0 and then the standard range on week 8and 10.
Downward. The control animals showed a tendency towards improvement of the
score. OX 9 performed worse than the established standard on the week 4, 8 and 10. No
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other animal show a consistency in decreased performance as compared to the standard
range.
Foot Placement Accuracy Analysis (number of errors). The results of this analysis
are shown in a figure 5B. In the horizontal plane the rat OX 9, showed a strong tendency
to increase the amount of errors during the course of treatment, and exhibit higher % of
errors than the standard range on weeks 4, 8 and 10. The animal OX10 showed a
tendency to increase the number of errors between weeks 0 and 4, and exhibited higher %
of errors on week 2 and 4. However on the week 10 the % errors made by this rat felt
among the standard range.
Upward. The animal OX 9 showed a tendency to increase the % of errors between
week 0 and 8. However, only in the week 4 and 8 the % of errors was bigger than the
standard range. Furthermore OX 9 exhibited a decrease in % of error on week 10 and
was. On week 4, OX3 showed the increase in %error comparing to the control week,
however it was at border of the standard range. In the week 8 and 10, OX3 increased the
% of error even further, to a point it was outside of the standard range. OX10 animal
showed a tendency to decrease the number of errors from week 0 to week 4. On week 8
and 10, the % of error made by OX10 was higher than the standard range, as well as
higher than the % of error made by this animal on the week 0.
Downward. The animal OX9 showed a small decrease in the % of errors between
week 0 and 2. However in the following weeks, this rat showed a great increase in % of
errors, which was also much higher than the standard range. The OX10 animal exhibited
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a higher than the standard range % of error on the week 4 and 10. On week 8 the % of
errors made by this animal was within the range and lower than the original value.
Hind Foot Placement Precision
The results of this analysis are shown in a figure 5C.
Horizontal. The rat OX9 showed a higher % of errors in hind limb precision than
the standard range on each analyzed week after the treatment. Furthermore the OX9
showed the tendency to increase the % of errors over the time of the study. The OX 10
animal showed initially a deterioration of performance from week 0 to week 2 leading to
a higher than standard range % of errors in the hind limb precision. From week 2 until
week 8, OX 10 had a tendency to improve its performance as a result on the week 8 it fell
into the standard range. On the week 10 the % error for OX 10 was, again outside of the
range.
Upward. The OX 9 rat showed a greater than the standard range % of errors in the
hind limb precision on the week 4, 8 and 10. Furthermore, these values were also greater
than the % of error in the control week.
Downward. The OX 9 was the only rat that showed a consistent tendency and a
higher % of errors in hind limb precision in weeks: 4, 8, and 10. Additionally the values
in week 8 and 10 were also higher than the original value from the control week.
Hind Limb Idleness
The results of this analysis are shown in figure 5D.
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Figure 5
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Fig.5. Ladder Rung test results. The control data is represented as a mean value for all
five control rats ±0.95 confidence interval. The OX-animal data is presented as a
scatterplot, where each point represents one animal. Only the animals that showed
consistent variation from the control mean±0.95 CI were identified on the plot. (A) The
average scores from the week 0 was presented as 0 and the average % change in scores in
following weeks was plotted against time (weeks) for horizontal, upward and downward
planes respectively. The positive values indicate improvement whereas negative,
deterioration as compared to control week 0. (B) The errors per steps ratio, presented as
%of errors, in horizontal, upward and downward plane. Higher values in in this analysis
indicate a greater amount of errors per step. (C) The hind limb precision placement
represented as the % of hind limb steps when the rat did not placed the hind foot at the
same rung as corresponding front paw in horizontal, upward and downward planes. The
lower values in this test represent a better precision. (D) The hind limb idling in
horizontal, upward and downward plane. The number of times the hind limbs were idle is
presented in this plot as the ratio of idling occurrence per a step cycle. The higher values
indicate more idling.
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Horizontal. The OX 2 and OX 6 exhibited the tendency to decrease the % of
idling, but revealed higher than the standard range ratio of idling/cycles consistently
starting on week 4.
Upward. The animal OX6 showed a tendency to lower the number of hind limb
idleness throughout the study. At the same time it exhibited a higher than the standard
range ration of idling/cycles on week 4, 8 and 10.
Downward. The rats OX 2, OX 6 and OX 8 exhibited a higher ratio of idling
consistently starting on week 4, but lower than their original values from the week 0.
Modified Balance Beam
The results of this test are presented in the figure 6.
Foot Placement Scoring. There were no OX animals that consistently performed
worse than the established standard range. Additionally, the score in all OX animals for
the week 8 and 10 were improved comparing to the week 0, i.e. the % change in score for
all OX animals was above 0. The OX 1 animal performed worse than the standard range
in week 2, but in the following weeks the % of change was within the standard range and
higher than the control week. The OX5 rat showed a lower % of change in score than the
standard range only in week 2. Although within the range, the % of change in week 10
was negative, indicating deterioration comparing to the week 0.

33

Figure 6
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Fig.6. Modified Balance Beam test results. The control data is represented as a mean
value for all five control rats ±0.95 confidence interval. The OX-animal data is presented
as a scatterplot, where each point represents an individual rat. Only the animals that
showed consistent variation from the control mean±0.95 CI were identified on the plot.
(A) The % change in foot placement score. The positive values indicate improvement
whereas negative, deterioration as compared to control week 0. (B) Errors to steps ratio
occurring during crossing the modified beam, presented as the % of error. Higher values
indicate more mistakes made by rats during crossing the beam. (C) The error/turn ratio.
The errors committed during stepping, or hopping over the 90 ˚corner was calculated and
expressed as a percentage of turns with an error. The higher values indicate more
mistakes done during this action. (D) Corner approach analysis. The ratio of three
different approaches (precise, cut and hop), was calculated and presented on separate
plots in order to visualize the change, and compare it between the control and OX-treated
rats.
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Foot Placement Accuracy. The animal OX2 showed a higher % of error than the
standard range in weeks: 2, 4, and 8. Additionally, it also showed an increase in % of
errors in week 2 and 4 comparing to the week 0.The animal OX4 showed a higher than
the standard range % of errors on week 2 and 8. In week 4 and 10 this animal did not
show a higher than the control range % and furthermore, the % of errors in week 10 was
smaller than in the control week.
Corner Analysis. There was no OX animal that showed a consistent increase in
error during stepping and/or hopping over the corner. The OX3 and OX6 animal were the
only ones that showed a greater %of errors in two weeks (see figure 6C). The animal
OX3 approached the turn in the precise manner more often than the standard range in
week 4 and 10. The rats: OX4, OX5, OX9 and OX10 exhibited this type of turn more
often than the control range in the week 10. Furthermore all of these animals increased
the carful way of turning, comparing to the week 0. On the week 10 the rats: OX1, OX3,
OX5, OX6 and OX7 exhibit lower % of the cut approach to the turn than the standard
range. Additionally all of them performed less “cutting” the corner than on the week 0.
The animal OX3 showed a tendency to decrease the amount of the “Cut corners”. All of
the OX animals performed less hops than the control range. The OX5 animal performed
less hops than the standard range in every analyzed week. The OX 3 animal also
performed less hops on the week 8. The mean control data with 0.95CI serving as a
standard range, along with the scatterplot for the OX animals is shown in the figure 6D.
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Paw Placement
The animal OX2 showed consistently a higher than the standard range, % of trails
with an error starting with the week 4 till the end of the study. Additionally, in those
weeks (except week 3) the % of error was also higher than the original value. The animal
OX4 showed an out-of- range high % error in week 1, 5 and 6, and all of them were
higher than in the control week. The mean control data along with 0.95CI was plotted on
the same graph as the OX scatterplot data, and presented in the figure 7.
Differentiating between symptomatic and asymptomatic OX-treated rats
Based on the standard range the rat OX9 was diagnosed as symptomatic in 8 out
of 15 tests, and somehow symptomatic in 1 of them; OX 6 was considered symptomatic
in 4 tests and somehow symptomatic in 1; OX10 was symptomatic in 4 tests, and
somehow symptomatic in 2; OX2 and OX3 were both symptomatic in 3 tests; OX7 was
symptomatic in 1 test and also somehow symptomatic in 1; OX8 was symptomatic only
in one test. Additionally the approach to the corner revealed a consistent lower % of hops
in OX5 rat starting week 2. OX3 have shown a lower % of hops in week 8 and 10. All the
OX rats had a lower than the standard range % of hops in week 10. The summary of this
analysis is presented in the table 4.
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Figure 7
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Fig.7. Paw Placement test results. The control data is represented as a mean value for all
five control rats ±0.95 confidence interval. The OX-animal data is presented as a
scatterplot, where each point represents an individual rat. Only the animals that showed
consistent variation from the control mean±0.95 CI were identified on the plot. The % of
error in this plot indicates the number of times the rat failed to immediately place its paw
back on the surface and/or failed to reach the surface resulting in swipe.
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Table 4
Table 4. Symptomatic and “Somehow” Symptomatic Animals as revealed in this study
Consistently Symptomatic
Somehow Symptomatic
Test
Animals
Animals
H LR change in score

OX3, OX9, OX10

U LR change in score

OX3, OX7, OX9

D LR change in score

OX9

OX10

H LR errors/steps

OX9

OX 10

U LR errors/steps

OX3, OX10

OX9

D LR errors/steps

OX9

OX10

H LR Hind Limb
precision

OX9

OX10

U LR Hind Limb
precision

OX9

D LR Hind Limn
precision

OX9

H LR Hind Limb
idling

OX2, OX6

U LR Hind Limb
idling

OX6

D LR Hind Limb
idling

OX2, OX6, OX8

Paw Placement

OX2
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OX7

IV.

DISCUSSION

It has been nearly 30 years since the oxaliplatin was first introduced to clinical
trials in 1986 (Mathe, et al., 1986). The reports of its neurotoxic chronic and acute effects
followed soon after. However, despite such a long time of research, the animal model that
would address the chronic, dose-limiting, sensorimotor symptoms has not been yet
established. This study provides the first step towards developing such a model.
Furthermore, we were able to reproduce the results seen in clinical studies, where
“several subjects reported symptoms that interfered with drinking, walking or performing
dexterity task” with no apparent evidence of CIPN (Burakgazi, et al., 2011). In this study
none of the OX treated animals manifested signs of CIPN; however, they exhibited an
apparent failure to sustain the firing during a static muscle stretch. Although the
presented data did not show prominent sensorimotor deficits in all OX-rats, several
treated animals exhibited consistent difficulties performing tasks that are known to
address proprioceptive abilities, sensorimotor integration and movement coordination.
For each of the tests, the rats were considered to show sensorimotor deficits, i.e.
they were symptomatic if they showed a tendency to perform worse than the standard
range (control mean value±0.95 confidence interval) that persisted till the week 10. Using
this system, 7 out of 10 animals were identified as symptomatic at least in one of the
tests. The animal that was diagnosed as symptomatic most often was OX9 and showed
decreased performance in 8 out 16 tests (Table 4).
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The Ladder Rung Task is a common sensorimotor test designed to detect
proprioceptive and sensorimotor impairments (Metz and Whishaw, 2002). It has been
widely used to investigate skilled walking, limb placement and limb coordination in
variety of sensorimotor deficits models such as: Parkinson’s Disease (Faraji and Metz,
2007) stroke model (Riek-Burchardt, et al., 2004), and spinal cord injuries (Martinez, et
al., 2010; Ghosh, et al., 2009). Furthermore, the rungs from the ladder were positioned
irregularly, and changed from trial to trial, therefore the animals were not capable of
anticipating the rung location and learning a specific gait pattern, as a result, each step
required adjustment in paw placement and stride length. The animals with a corrupted
proprioceptive feedback that prevents them from precise control of trajectory of their
limbs (Prochazka and Ellaway, 2012; Proske and Gandevia 2009a) would have to
experience lower scores, higher number of errors, decreased hind limb precision and
increased idling compare to the intact animals. The OX animals diagnosed as
symptomatic performed worse than the control range and often below their original
scores, indicating that there is a correlation between the OX-treatment and low level of
performance. Furthermore, the animal OX9, when diagnosed as symptomatic, always
performed bellow its original scores showing not only lack of improvement but
worsening of the performance, which strongly suggests a proprioceptive deficit in this
animal.
Additionally, The Modified Balance Beam Test revealed the tendency of OX
animals to use a safer approach during turning. All the OX animals were in the lower
values of the standard range in the terms of the amount of hops. During the precise turn,
the animals stepped as close to the edge of the corner as possible, as a result they
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repositioned their bodies, before they continued on the next straight path. This strategy
provided them with lower probability of error. In contrast, the correct hop or cut required
steeping from a straight path to a perpendicular path. In the presence of proprioceptive
deficits such an action requires proper positioning of limbs in the space. Although this
data is hard interpret, due to the wide range in control animals, it seems like OX animals
tend to choose more secure ways of approaching the corners.
The incidence of sensorimotor impairment in OX treated patients is 90% (Bennet
et al., 2009). However the dose at which this deficit starts to manifests, as well as the
symptoms are variable between patients (Park et al., 2011). Therefore, the inconsistency
that we observed in behavioral tests corresponds to the inconsistency seen in patients.
Furthermore, the dose-limiting sensorimotor deficits develop in patients with the
cumulative OX dose ≥540-850mg/m2 (Gamelin, et al., 2002; Andre, et al., 1999). In rats
this dose range corresponds to approximately 90-141.6mg/kg (Freireich, et al., 1966).
Therefore, the reason why we have not observed more prominent sensory symptoms
could be that the cumulative dose was not sufficient enough to elicit functional deficits.
In order to create a better animal model to address the OX-induced chronic sensorimotor
deficits, it is necessary to establish a dosing regimen that would correspond to the one
given in humans. It has been previously shown that not only the amount of a single
and/or cumulative dose but also the schedule between the injections has a great influence
on the OX-induced toxicity (Cavaletti, et al. 2001).
The reason why the other rats did not show prominent sensorimotor deficit,
despite showing the evidence of impair proprioceptive signaling, could be that we did not
use the appropriate behavioral tests to address this deficit more clearly. The IA afferents
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in OX-treated animals show cessation of the firing during the static phase of the muscle
stretch. The dynamic phase is intact. The tests that we have used were mostly dynamic
and required rats to walk, which would give us a false negative results about
sensorimotor impairment. Therefore, for further investigation of the proprioceptive
deficits in OX-treated rats, it is crucial to carefully choose and/or design the behavioral
tests to ensure that they target the impaired proprioception during the static phase.
Another factor that could have a negative impact on our study was the sample
size, especially the control sample size. We only used 5 control rats that we have
averaged and created a standard range based on the mean value±0.95 confidence interval.
The small sample size, created a situation like the one in Modified Beam that the
confidence interval stretched over the values from 5% to 70%. A bigger sample would
allow us to exclude the outliers, which possibly could create narrower control range.
In conclusion, the data presented in this study showed evidence of sensorimotor
deficits in one animal, and suggested such impairment in six, without the sign of CIPN.
Considering the variability of symptoms seen in patients, the lack of consistency in rats is
expected in a good model. Therefore, although this study did not show direct correlation
between the symptoms and corrupted proprioceptive encoding, it succeeded in creating
an adequate rodent model for studying the sensorimotor deficits following OX treatment.
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